AMENDMENT TO THE CLAIMS

1-51. (Canceled)

52. (Currently amended) A composition, for delivery of a therapeutic agent to a neuronal cell, comprising:

a therapeutic agent which inhibits at least one member of the Rho group of GTPases,

a neuronal cell targeting component, which component comprises a Hc domain of botulinum C1 toxin, or a fragment thereof which retains the function of the native Hc domain, and

a domain for translocation of the therapeutic agent into a cell,

wherein the Hc domain has been made recombinantly, ~~and~~

the therapeutic agent is an ADP-ribosyltransferase, and

the therapeutic agent is selected from the group consisting of:

a C3 enzyme having an amino acid sequence selected from the group consisting of SEQ ID Nos: 1-10, and

a C3 enzyme selected from the group consisting of *S. aureus* C3 exoenzyme 1 isoform, *S. aureus* C3 exoenzyme 2 isoform and *C. botulinum* C3 exoenzyme.

53. (Previously Presented) A composition according to Claim 52, wherein the translocation domain is derived from a clostridial source.

54. (Withdrawn – Previously Presented) A composition according to Claim 52, wherein the translocation domain is derived from a non-clostridial source.

55. (Previously Presented) A composition according to Claim 53, wherein the translocation domain is derived from *C. botulinum, C. butylicum, C. argentinense* or *C. tetani*.

56. (Withdrawn – Previously Presented) A composition according to Claim 54, wherein the translocation domain comprises a translocation domain of diphtheria toxin, Pseudomonas exotoxin A, influenza virus haemagglutinin fusogenic peptides or amphiphilic peptides.

57. (Previously Presented) A composition according to Claim 52, wherein the translocation domain comprises a member selected from the group consisting of botulinum C1 toxin and fragments thereof, and diphtheria toxin and fragments thereof.

58. (Previously Presented) A composition according to Claim 52, wherein the translocation domain is a membrane disrupting peptide.

59-63. (Cancelled)

64. (Previously Presented) A composition according to Claim 52, wherein the therapeutic agent and the Hc domain are joined to each other directly or via a linker molecule.

65. (Previously Presented) A composition according to Claim 52, wherein the therapeutic agent, the Hc domain and the translocation domain are joined to each other directly or via a linker molecule.

66. (Previously Presented) A composition according to Claim 64, wherein the linker molecule is selected from the group consisting of the interdomain linker of cellulase,

collagen spacer, trypsin-sensitive diphtheria toxin peptide, and linker molecules having an amino acid sequence of SEQ ID Nos: 16-27.

67. (Previously Presented) A composition according to Claim 65, wherein the linker molecule is selected from the group consisting of the interdomain linker of cellulase, collagen spacer, trypsin-sensitive diphtheria toxin peptide, and linker molecules having an amino acid sequence of SEQ ID Nos: 16-27.

68. (Previously Presented) A composition according to Claim 52, wherein the composition is a single polypeptide.

69. (Previously Presented) A composition according to Claim 52, wherein the composition is a dichain polypeptide.

70. (Previously Presented) A composition according to Claim 52, wherein the composition is a suspension, emulsion, solution or a freeze-dried powder.

71. (Previously Presented) A composition according to Claim 52, further comprising a pharmaceutically acceptable liquid.

72. (Withdrawn – Previously Presented) A method of making a composition according to Claim 52, comprising expressing a DNA encoding the therapeutic agent and the neuronal cell targeting domain.

73. (New) A composition according to Claim 53, wherein the therapeutic agent and the Hc domain are joined to each other directly or via a linker molecule.

74. (New) A composition according to Claim 53, wherein the therapeutic agent, the Hc domain and the translocation domain are joined to each other directly or via a linker molecule.

75. (New) A composition according to Claim 53, wherein the composition is a single polypeptide.

76. (New) A composition according to Claim 53, wherein the composition is a dichain polypeptide.

77. (New) A composition according to Claim 53, wherein the composition is a suspension, emulsion, solution or a freeze-dried powder.

78. (New) A composition according to Claim 53, further comprising a pharmaceutically acceptable liquid.